Primer ID informs next-generation sequencing platforms and reveals preexisting drug resistance mutations in the HIV-1 reverse transcriptase coding domain

AIDS Research and Human Retroviruses

Volumn 31, Issue 6, 2015, Pages 658-668

  Keys, Jessica R ^a   Zhou, Shuntai ^b   Anderson, Jeffrey A ^b,c   Eron, Joseph J ^b   Rackoff, Lauren A ^b   Jabara, Cassandra ^b,d   Swanstrom, Ronald ^b  

^a University of North Carolina at Chapel Hill   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c BRISTOL MYERS SQUIBB   (United States)

^d Abbott Molecular Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EFAVIRENZ; NEVIRAPINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; PRIMER DNA; REVERSE TRANSCRIPTASE, HUMAN IMMUNODEFICIENCY VIRUS 1;

AMPLICON; ANTIVIRAL RESISTANCE; ANTIVIRAL THERAPY; ARTICLE; CODON; CONSENSUS SEQUENCE; CONTROLLED STUDY; DNA SYNTHESIS; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MAJOR CLINICAL STUDY; MALE; NEXT GENERATION SEQUENCING; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; VIRUS MUTATION; ADULT; CLASSIFICATION; COHORT ANALYSIS; DRUG EFFECTS; GENETIC VARIATION; GENETICS; HIGH THROUGHPUT SEQUENCING; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; ISOLATION AND PURIFICATION; MIDDLE AGED; MUTATION; VIROLOGY;

ADULT; COHORT STUDIES; DNA PRIMERS; DRUG RESISTANCE, VIRAL; FEMALE; GENETIC VARIATION; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HIV INFECTIONS; HIV REVERSE TRANSCRIPTASE; HIV-1; HUMANS; MALE; MIDDLE AGED; MUTATION;

EID: 84930239847     PISSN: 08892229     EISSN: 19318405     Source Type: Journal    
DOI: 10.1089/aid.2014.0031     Document Type: Article

References (37)

1. Buchacz K, Baker RK, Palella FJ Jr, et al.: AIDS-defining opportunistic illnesses in US patients, 1994-2007: A cohort study. AIDS 2010;24(10):1549-1559.
2. Egger M, May M, Chene G, et al.: Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: A collaborative analysis of prospective studies. Lancet 2002;360(9327):119-129.
3. Moore RD, Keruly JC, and Bartlett JG: Improvement in the health of HIV-infected persons in care: Reducing disparities. Clin Infect Dis 2012;55(9):1242-1251.
4. Clavel F and Hance AJ: HIV drug resistance. N Engl J Med 2004;350(10):1023-1035.
5. Hirsch MS, Gunthard HF, Schapiro JM, et al.: Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 Recommendations of an International AIDS Society-USA Panel. Clin Infect Dis 2008;47(2):266-285.
6. Brenner BG, Roger M, Routy JP, et al.: High rates of forward transmission events after acute/early HIV-1 infection. J Infect Dis 2007;195(7):951-959.
7. Yerly S, Junier T, Gayet-Ageron A, et al.: The impact of transmission clusters on primary drug resistance in newly diagnosed HIV-1 infection. AIDS 2009;23(11):1415-1423.
8. Bansi L, Geretti AM, Dunn D, et al.: Impact of transmitted drug-resistance on treatment selection and outcome of firstline highly active antiretroviral therapy (HAART). J Acquir Immune Defic Syndr 2010;53(5):633-639.
9. Poggensee G, Kucherer C, Werning J, et al.: Impact of transmission of drug-resistant HIV on the course of infection and the treatment success. Data from the German HIV-1 Seroconverter Study. HIV Med 2007;8(8):511-519.
10. Wittkop L, Gunthard HF, de Wolf F, et al.: Effect of transmitted drug resistance on virological and immunological response to initial combination antiretroviral therapy for HIV (EuroCoord-CHAIN joint project): A European multicohort study. Lancet Infect Dis 2011;11(5):363-371.
11. Panel on Antiretroviral Guidelines for Adults and Adolescents: Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. U.S. Department of Health andHuman Services.March 12, 2013. 2013:1-267.Available at www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentsGL.pdf. Accessed March 2013.
12. Palmer S, Kearney M, Maldarelli F, et al.: Multiple, linked human immunodeficiency virus type 1 drug resistance mutations in treatment-experienced patients are missed by standard genotype analysis. J Clin Microbiol 2005;43(1): 406-413.
13. Goodman DD, Zhou Y, Margot NA, et al.: Low level of the K103N HIV-1 above a threshold is associated with virological failure in treatment-naive individuals undergoing efavirenz-containing therapy. AIDS 2011;25(3): 325-333.
14. Jakobsen MR, Tolstrup M, Sogaard OS, et al.: Transmission of HIV-1 drug-resistant variants: Prevalence and effect on treatment outcome. Clin Infect Dis 2010;50(4): 566-573.
15. Johnson JA, Li JF, Wei X, et al.: Baseline detection of lowfrequency drug resistance-associated mutations is strongly associated with virological failure in previously antiretroviral-naive HIV-1-infected persons. Antivir Ther 2006; 11(5):S79.
16. Lataillade M, Chiarella J, Yang R, et al.: Prevalence and clinical significance of HIV drug resistance mutations by ultra-deep sequencing in antiretroviral-naive subjects in the CASTLE study. PLoS One 2010;5(6):e10952.
17. Simen BB, Simons JF, Hullsiek KH, et al.: Lowabundance drug-resistant viral variants in chronically HIV-infected, antiretroviral treatment-naive patients significantly impact treatment outcomes. J Infect Dis 2009; 199(5):693-701.
18. Metzner KJ, Rauch P, Braun P, et al.: Prevalence of key resistance mutations K65R, K103N, and M184V as minority HIV-1 variants in chronically HIV-1 infected, treatment-naive patients. J Clin Virol 2011;50(2):156-161.
19. Metzner KJ, Rauch P, Walter H, et al.: Detection of minor populations of drug-resistant HIV-1 in acute seroconverters. AIDS 2005;19(16):1819-1825.
20. Hoffmann C, Minkah N, Leipzig J, et al.: DNA bar coding and pyrosequencing to identify rare HIV drug resistance mutations. Nucleic Acids Res 2007;35(13):e91.
21. Gilles A, Meglecz E, Pech N, et al.: Accuracy and quality assessment of 454 GS-FLX titanium pyrosequencing. BMC Genom 2011;12:245.
22. Wang C, Mitsuya Y, Gharizadeh B, et al.: Characterization of mutation spectra with ultra-deep pyrosequencing: Application to HIV-1 drug resistance. Genome Res 2007; 17(8):1195-1201.
23. Kanagawa T: Bias and artifacts in multitemplate polymerase chain reactions (PCR). J Biosci Bioeng 2003;96(4): 317-323.
24. Liu SL, Rodrigo AG, Shankarappa R, et al.: HIV quasispecies and resampling. Science 1996;273(5274):415-416.
25. Jabara CB, Jones CD, Roach J, et al.: Accurate sampling and deep sequencing of the HIV-1 protease gene using a Primer ID. Proc Natl Acad Sci USA 2011;108(50):20166-20171.
26. Napravnik S, Eron JJ Jr, McKaig RG, et al.: Factors associated with fewer visits for HIV primary care at a tertiary care center in the Southeastern U.S. AIDS Care 2006; 18(Suppl 1):S45-50.
27. Chenna R, Sugawara H, Koike T, et al.: Multiple sequence alignment with the Clustal series of programs. Nucleic Acids Res 2003;31(13):3497-3500.
28. Tamura K, Peterson D, Peterson N, et al.: MEGA5: Molecular evolutionary genetics analysis using maximum likelihood, evolutionary distance, and maximum parsimony methods. Mol Biol Evol 2011;28(10):2731-2739.
29. Bennett DE, Camacho RJ, Otelea D, et al.: Drug resistance mutations for surveillance of transmitted HIV-1 drugresistance: 2009 update. PLoS One 2009;4(3):e4724.
30. Varghese V, Wang E, Babrzadeh F, et al.: Nucleic acid template and the risk of a PCR-induced HIV-1 drug resistance mutation. PLoS One 2010;5(6):e10992.
31. Williams RL: A note on robust variance estimation for cluster-correlated data. Biometrics 2000;56(2):645-646.
32. Kuritzkes DR, Lalama CM, Ribaudo HJ, et al.: Preexisting resistance to nonnucleoside reverse-transcriptase inhibitors predicts virologic failure of an efavirenz-based regimen in treatment-naive HIV-1-infected subjects. J Infect Dis 2008;197(6):867-870.
33. Bentley DR, Balasubramanian S, Swerdlow HP, et al.: Accurate whole human genome sequencing using reversible terminator chemistry. Nature 2008;456(7218):53-59.
34. Krueger F, Andrews SR, and Osborne CS: Large scale loss of data in low-diversity illumina sequencing libraries can be recovered by deferred cluster calling. PLoS One 2011;6(1):e16607.
35. Wang J, Bambara RA, Demeter LM, and Dykes C: Reduced fitness in cell culture of HIV-1 with nonnucleoside reverse transcriptase inhibitor-resistant mutations correlates with relative levels of reverse transcriptase content and RNase H activity in virions. J Virol 2010;84(18):9377-9389.
36. Wang J, Li D, Bambara RA, et al.: L74V increases the reverse transcriptase content of HIV-1 virions with nonnucleoside reverse transcriptase drug-resistant mutations L100I + K103N and K101E + G190S, which results in increased fitness. J Gen Virol 2013;94(Pt 7):1597-1607.
37. Li JZ, Paredes R, Ribaudo HJ, et al.: Low-frequency HIV-1 drug resistance mutations and risk of NNRTI-based antiretroviral treatment failure: A systematic review and pooled analysis. JAMA 2011;305(13):1327-1335.